Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.69
- Piotroski Score 4.00
- Grade Buy
- Symbol (VVOS)
- Company Vivos Therapeutics, Inc.
- Price $3.20
- Changes Percentage (8.47%)
- Change $0.25
- Day Low $3.00
- Day High $3.27
- Year High $48.79
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$11.05
- Trailing P/E Ratio -0.22
- Forward P/E Ratio -0.22
- P/E Growth -0.22
- Net Income $-13,583,000
Income Statement
Quarterly
Annual
Latest News of VVOS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
Vivos Therapeutics Inc (NASDAQ:VVOS) had positive Q3 2024 results, with increased revenue and gross margin, reduced operating expenses, and FDA clearance for treating severe OSA....
By Yahoo! Finance | 1 week ago
